Effectiveness of High-Flow Nasal Cannula on Pulmonary Rehabilitation in Subjects with Chronic Respiratory Failure

Yuichi Chihara (yc.r03107@gmail.com)
National Hospital Organization Minami-Kyoto Hospital
https://orcid.org/0000-0003-0896-283X

Tomomasa Tsuboi
National Hospital Organization Minami-Kyoto Hospital

Kensuke Sumi
National Hospital Organization Minami-Kyoto Hospital

Atsuo Sato
National Hospital Organization Minami-Kyoto Hospital

Research article

Keywords: Chronic respiratory failure, Exercise training, High-flow nasal cannula

DOI: https://doi.org/10.21203/rs.3.rs-55544/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Backgrounds:** There are no clinical data comparing the effect of exercise training using both high fraction of inspired oxygen (F\textsubscript{I}O\textsubscript{2}) and high flow through a high-flow nasal cannula (HFNC) with that of ordinary supplemental oxygen on exercise capacity in subjects with chronic respiratory failure (CRF) receiving long-term oxygen therapy (LTOT).

**Methods:** In this randomized study, 32 patients with CRF receiving LTOT were assigned to undergo 4 weeks of exercise training on a cycle ergometer using an HFNC (flow: 50 L/min) with a F\textsubscript{I}O\textsubscript{2} of 1.0 (HFNC group; n=16) or ordinary supplemental oxygen via a nasal cannula (flow: 6 L/min) (oxygen group; n=16). Before and after 4 weeks of exercise training, a 6-min walking test, constant-load test, and blood sampling were performed.

**Results:** Prior to exercise training, the endurance time of the constant-load exercise test using an HFNC was significantly longer than that reported with prescribed oxygen in daily LTOT (p=0.004) or a 6 L/min nasal cannula (p=0.0003). Following 4 weeks of exercise training, change in the 6-min walking distance was significantly greater in the HFNC versus the oxygen group (55.2±69.6 m vs. –0.5±87.3 m, respectively; p=0.04). The plasma levels of adrenaline, noradrenaline, and serum C-reactive protein were significantly decreased only in the HFNC group, after 4 weeks of exercise training.

**Conclusions:** Despite heterogeneity in the effect among patients, exercise training using both high F\textsubscript{I}O\textsubscript{2} and high flow through an HFNC is a potentially superior exercise training modality for CRF patients receiving LTOT.

**Clinical Trial Registration** — http://www.clinicaltrials.gov. Unique identifier: NCT02804243. Registered 13 June 2016.

**Background**

Pulmonary rehabilitation reduces dyspnea, increases exercise capacity, and improves quality of life in patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease, bronchiectasis, and pulmonary hypertension [1–4]. High-intensity endurance exercise training (e.g., cycling or walking) is the most commonly applied exercise modality in pulmonary rehabilitation [5–7].

It has been observed that patients with advanced chronic respiratory failure (CRF) receiving long-term oxygen therapy (LTOT) have severe hypoxia during exercise training even if they receive relatively high flow rates of oxygen via a nasal cannula. In addition, the maximal flow rate of oxygen via a nasal cannula during exercise training is approximately 6 L/min. This is due to severe nasal dryness and pain induced by higher flow rates. Low-intensity exercise training has been applied to individuals with CRF who have difficulty in achieving their target intensity because of dyspnea and/or hypoxia. However, it led to insufficient exercise training effects compared with high-intensity exercise training.
Several new options to increase the effects of exercise training have been reported. It has been shown that hyperoxia during exercise training increased the peak work rate [8] or endurance time in the constant-load exercise test [9] in COPD patients. In other studies, exercise training using hyperoxia did not demonstrate a beneficial effect [10–13]. The administration of a high flow heated and humidified gas mixture through high-flow nasal cannula (HFNC) promotes higher and more stable inspiratory oxygen fraction values, decreases anatomical dead space, and generates a positive airway pressure that can improve ventilatory efficiency [14–16]. In addition, it reduces the effort of breathing and enhances patients’ comfort and tolerance [16–19]. In a previous study, the duration of the constant-load exercise test in COPD patients receiving LTOT was significantly improved after exercise training consisting of 20 supervised sessions in both the HFNC group and control group, whereas no significant difference between groups was observed in improvement in the duration of the constant-load exercise test [20]. In this study, both groups undergone exercise training at the same fraction of inspired oxygen ($F_{\text{I}O_2}$). Based on the beneficial effects of an HFNC, we postulated that high intensity exercise training using not only high flow but also high $F_{\text{I}O_2}$ through an HFNC may lead to an enhancement of exercise capacity in patients with advanced CRF receiving LTOT.

The aim of this randomized, prospective study was to compare the effect of 4 weeks of exercise training using both high $F_{\text{I}O_2}$ and high flow through an HFNC or supplemental oxygen via a nasal cannula on the exercise capacity (e.g., 6-min walking distance [6MWD]) of CRF patients receiving LTOT.

**Methods**

**Patients**

From June 2016 to May 2018, patients with CRF (aged 40–90 years) undergoing LTOT for $\geq$ 3 months and attending an in-patient rehabilitation program were eligible to participate in the study. Patients with a stable clinical condition (i.e., no exacerbation reported for 3 months prior to the study) and absence of the following exclusion criteria: history of cardiovascular disease (e.g., myocardial infarction or ischemic heart disease, diabetes mellitus under treatment with hypoglycemic agents or insulin, neurological disorders, renal dysfunction (serum creatinine $\geq$ 1.2 mg/dL), and unable to undergo rehabilitation were enrolled.

In this prospective study, we assessed 42 consecutive patients with CRF receiving LTOT. Prior to enrollment, all patients underwent a 2-week screening period. Of those, seven patients were excluded (two with acute exacerbation, three with history of cardiovascular disease, and two who were unable to undergo rehabilitation), and three patients declined to participate. Thus, the remaining 32 clinically stable CRF patients receiving LTOT were enrolled (Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02804243). This study was approved by the Ethics Committee of the National Hospital Organization Minami-Kyoto Hospital. All patients provided written informed consent prior to their participation.
Study design

On day 1, arterial blood gases (ABGs) were obtained in the supine position under a prescribed flow of oxygen via a nasal cannula and patients underwent a 6-min walking test (6MWT). On day 2, venous blood samples were obtained in the fasting state in the morning and examined for C-reactive protein (CRP), and plasma catecholamine levels. Pulmonary function tests were performed using the CHESTAC system (Chest M.I. Inc., Tokyo, Japan). In addition, patients underwent an incremental-load exercise test under prescribed oxygen on a cycle ergometer (Aerobike75XL, COMBI, Tokyo, Japan) to assess their maximal exercise capacity. In the following 3 days, the patients underwent (in random order) three constant-load exercise tests with a prescribed flow of oxygen via a nasal cannula, a flow of 6 L/min of oxygen via a nasal cannula, or an HFNC at a flow of 50 L/min with F\textsubscript{I\textsubscript{O\textsubscript{2}}} of 1.0. The HFNC delivered a heated and humidified gas through an Optiflow system (Fisher and Paykel Healthcare, Auckland, New Zealand) using large-bore bi-nasal prongs.

After the constant-load exercise tests, patients completed a 4-week period of exercise training (five sessions per week) using the same workload achieved during the constant-load exercise tests. In the HFNC group, the HFNC was set at maximum F\textsubscript{I\textsubscript{O\textsubscript{2}}} (F\textsubscript{I\textsubscript{O\textsubscript{2}}} of 1.0) and near-maximum inspiratory flow rate (50 L/min) to assess its maximum effects. In the oxygen group, the flow rate of oxygen via a nasal cannula was set at the maximal flow rate (6 L/min).

Venous blood sampling, ABGs, pulmonary function tests and 6MWT on prescribed oxygen were conducted after 4 weeks of exercise training. In the following 3 days, subjects also underwent (in random order) three constant-load exercise tests using the same workload with that of the baseline assessment with prescribed oxygen in daily LTOT, a 6 L/min nasal cannula, or an HFNC at F\textsubscript{I\textsubscript{O\textsubscript{2}}} of 1.0 and 50 L/min.

The primary outcome was change in the 6MWD prior to and following 4 weeks of exercise training. The secondary outcome was change in the duration of constant-load exercise test prior to and after 4 weeks of exercise training.

6MWT

The 6MWT was performed under prescribed oxygen in daily LTOT. According to the guidelines of the American Thoracic Society [21], patients were encouraged using standard methodology every minute of the 6MWT. A pulse oximeter (Anypal Walk, Fukuda Denshi, Tokyo, Japan) with a finger probe was used to measure oxygen saturation by pulse oximetry (Sp\textsubscript{O\textsubscript{2}}) and the pulse rate during the 6MWT. In addition, a modified Borg scale [22] was used to quantify the levels of dyspnea perceived by patients at each minute during the 6MWT.

Exercise testing
Both incremental- and constant-load exercise tests were performed with continuous monitoring of SpO$_2$ and the pulse rate on a cycle ergometer. In addition, continuous transcutaneous carbon dioxide partial pressure (PtcCO$_2$) monitoring was performed using a TOSCA measurement system and TOSCA 500 monitor (Radiometer, Copenhagen, Denmark) [23, 24]. After automated calibration, the TOSCA monitor was attached to the right or left ear lobe. PtcCO$_2$ monitoring was initiated after at least 10 min of equilibration. The incremental-load exercise test was performed according to the appropriate Japanese guidelines [25]. The incremental-load exercise test under prescribed oxygen in daily LTOT was initiated at 5 watts and increased by 5 watts every 2 minutes until the patient's SpO$_2$ was $\leq 85\%$, the pulse rate was $\geq 135$ beats/min, or the modified Borg scale for dyspnea was $\geq 5$. Prior to and following 4 weeks of exercise training, the patients performed three constant-load exercise tests at 80% of the maximum workload achieved with the incremental-load exercise test, with prescribed oxygen in daily LTOT, 6 L/min via a nasal cannula, or an HFNC at F$_{O_2}$ of 1.0 and 50 L/min. The criteria for the termination of the constant-load exercise test were the same as those for the incremental-load exercise test. The SpO$_2$, pulse rate, and PtcCO$_2$ were measured at 6 min of the constant-load exercise test. All exercise testing was performed in the afternoon.

**Exercise training**

The patients performed supervised pulse oximeter-monitored continuous exercise training (5 sessions per week) receiving 6 L/min using a nasal cannula or an HFNC at F$_{O_2}$ of 1.0 and 50 L/min. All training sessions were conducted on the same cycle ergometer and supervised by medical staff. Initially, the workload of the exercise training was the same as that of the constant-load exercise test. The criteria for the termination of exercise training sessions were SpO$_2$ $\leq 85\%$, pulse rate $\geq 135$ beats/min, or modified Borg scale for dyspnea $\geq 5$. Whenever the duration of an exercise training session was $\geq 30$ minutes, the workload of the subsequent session was increased by 5 watts.

**Randomization**

This study was randomized via blinded envelope prior to the initiation of the study.

**Power analysis**

Based on a previous study [26], differences of 30 meters of change in the 6MWD prior to and following 4 weeks of exercise training between the HFNC group and the oxygen group were decided to be clinically significant, and a standard deviation of 30 meters was expected. The sample size was set to achieve 80% power at a 5% significance level. The calculated sample size in each group was 16 subjects.
Data were analyzed using the JMP 9.0 software (SAS Institute, Inc. Cary, NC, USA), and values are expressed as mean ± standard deviation or absolute numbers and percentages. We compared subject characteristics, the results of the 6MWT and constant-load exercise test, and other parameters between the HFNC and oxygen groups. Continuous variables were tested using the unpaired t test or Mann–Whitney U test. Categorical variables were compared using the $\chi^2$ test or Fisher’s exact test. To investigate changes in the 6-min walk distance, constant load exercise test, and other parameters prior to and after 4 weeks of exercise training in each group, comparisons of data between those two time points were tested using a paired t test. A p < 0.05 denoted statistical significance.

**Results**

**Patient characteristics**

Figure 1 shows the study flow chart of this randomized study. In this study, 32 CRF patients receiving LTOT were randomly assigned to undergo 4 weeks of exercise training using an HFNC (n = 16) or a 6 L/min nasal cannula (n = 16). The characteristics of the patients are summarized in Table 1. The cause of CRF was COPD (n = 13), interstitial pulmonary fibrosis (IPF) (n = 15), or bronchiectasis (n = 4).
|                                  | HFNC group (n = 16) | Oxygen group (n = 16) | p value |
|----------------------------------|---------------------|-----------------------|---------|
| Age                              | 76.6 ± 5.7          | 76.0 ± 6.3            | 0.77    |
| Male                             | 13 (81.3)           | 11 (73.3)             | 0.69    |
| BMI                              | 21.9 ± 3.3          | 22.0 ± 3.7            | 0.97    |
| Underlying disease               |                     |                       | 0.23    |
| COPD                             | 6 (37.5)            | 7 (43.8)              |         |
| IPF                              | 9 (56.3)            | 6 (37.5)              |         |
| Bronchiectasis                   | 1 (6.2)             | 3 (18.7)              |         |
| %VC (%)                          | 72.2 ± 15.5         | 74.8 ± 18.8           | 0.68    |
| FEV1/FVC (%)                     | 66.7 ± 27.2         | 61.6 ± 23.2           | 0.58    |
| %DL_{CO} (%)                     | 55.4 ± 18.5         | 60.8 ± 23.7           | 0.49    |
| Oxygen supply of LTOT during resting (L/min) | 1.6 ± 1.3          | 1.1 ± 0.9             | 0.17    |
| Oxygen supply of LTOT during exercise (L/min) | 3.2 ± 1.8          | 2.8 ± 1.3             | 0.54    |
| ABGs                             |                     |                       |         |
| pH                               | 7.401 ± 0.030       | 7.410 ± 0.036         | 0.46    |
| PaO2 (Torr)                      | 89.6 ± 22.0         | 82.7 ± 23.5           | 0.41    |
| PaCO2 (Torr)                     | 43.7 ± 5.2          | 41.7 ± 7.1            | 0.41    |
| Comorbidity                      |                     |                       |         |
| Hypertension                     | 8 (50.0)            | 11 (68.8)             | 0.28    |
| Dyslipidemia                     | 9 (56.3)            | 11 (68.8)             | 0.47    |
| Diabetes Mellitus                | 3 (18.8)            | 3 (18.8)              | 0.99    |
| Blood (fasting)                  |                     |                       |         |
| Adrenaline (pg/mL)               | 20.4 ± 14.7         | 20.9 ± 16.1           | 0.92    |
| Noradrenaline (pg/mL)            | 388.0 ± 228.4       | 370.7 ± 255.7         | 0.84    |
| CRP (mg/dL)                      | 0.59 ± 0.58         | 0.40 ± 0.47           | 0.32    |
There were no significant baseline differences between the two groups (Table 1). Similarly, 6MWD, the maximum workload or time of the incremental-load exercise test, and time of the constant-load exercise test under three conditions did not differ significantly between the two groups (Table 2).

Table 2
Results of the exercise test and 6-minute walking test prior to 4 weeks of exercise training, and the load and duration of exercise training

|                               | HFNC group (n = 16) | Oxygen group (n = 16) | p value |
|-------------------------------|---------------------|-----------------------|---------|
| Incremental-load exercise test: |                     |                       |         |
| Maximum workload (watt)       | 36 ± 10             | 32 ± 13               | 0.39    |
| Time (sec)                    | 793 ± 230           | 724 ± 289             | 0.47    |
| Constant-load exercise test:  |                     |                       |         |
| Time under the prescribed oxygen in daily LTOT (sec) | 876 ± 858 | 950 ± 837 | 0.82 |
| Time under the 6 L/min nasal cannula (sec) | 1065 ± 986 | 1083 ± 944 | 0.96 |
| Time under the HFNC (sec)     | 1473 ± 887          | 1586 ± 1058           | 0.75    |
| 6-minute walking distance (m) | 224.1 ± 109.4       | 210.1 ± 93.0          | 0.70    |
| Modified Borg Scale for dyspnea on 6MWT | 3.6 ± 2.5 | 3.6 ± 2.1 | 0.97 |
| Exercise training:            |                     |                       |         |
| Mean workload (watt)          | 34 ± 11             | 31 ± 11               | 0.52    |
| Mean time per session (sec)   | 1532 ± 282          | 1218 ± 367            | 0.01    |

mean ± standard deviation or number (%)

Abbreviations: LTOT, long-term oxygen therapy; 6MWT, 6-minute walking test
Constant-load exercise test under three conditions in all subjects

Figure 2 shows the results of the constant-load exercise test prior to exercise training in all patients. The duration of the constant-load exercise test using an HFNC was significantly longer than that reported with prescribed oxygen in daily LTOT (p = 0.004) or a 6 L/min nasal cannula (p = 0.0003) (Fig. 2-A). Moreover, there was no significant difference between the two conditions (prescribed oxygen in daily LTOT or a 6 L/min nasal cannula) in the duration of the constant-load exercise test (p = 0.15). The modified Borg scale for dyspnea at the termination of the constant-load exercise test under the HFNC tended to be lower compared with that observed under the 6 L/min nasal cannula (p = 0.07) (Fig. 2-B).

Six minutes after initiation of the constant-load exercise test, the SpO\textsubscript{2} was significantly higher and the pulse rate was significantly lower with HFNC versus those observed with prescribed oxygen in daily LTOT or 6 L/min nasal cannula (Fig. 3-A, 3-B). There were no significant differences between the three conditions in PtcCO\textsubscript{2} six minutes after initiation of the constant-load exercise test (Fig. 3-C).

Exercise training

All patients completed 20 sessions of exercise training. There was no significant difference in the mean workload during exercise training between the groups (HFNC group: 34 ± 11 watt vs. oxygen group: 31 ± 11 watt; p = 0.52). The mean duration of the exercise sessions was significantly longer in the HFNC group compared with the oxygen group (1,532 ± 282 sec vs. 1,218 ± 367 sec, respectively; p = 0.01) (Table 2). During 4 weeks of exercise training, none of the patients exhibited clinically significant respiratory deterioration, such as rapidly aggravating oxygenation or dyspnea.

Primary outcome: Change in the 6MWD after 4 weeks of exercise training

Following 4 weeks of exercise training, change in the 6MWD was significantly greater in the HFNC group compared with the oxygen group (55.2 ± 69.6 m vs. -0.5 ± 87.3 m, respectively; p = 0.04) (Table 3). Compared with the baseline values, the 6MWD was significantly increased in the HFNC group, but not in the oxygen group (Table 4, Fig. 4). Notably, change in the modified Borg scale for dyspnea at the termination of the 6MWT was not significantly different between the two groups (Table 3).
Table 3
Changes in 6-minute walking test, and constant-load exercise test between the two groups prior to and following 4 weeks of exercise training

|                              | HFNC group (n = 16) | Oxygen group (n = 16) | p value |
|------------------------------|---------------------|-----------------------|---------|
| Δ 6-minute walk distance (m) | 55.2 ± 69.6         | -0.5 ± 87.3           | 0.04    |
| Δ Modified Borg Scale for dyspnea on 6MWT | 0.0 ± 1.7 | 0.3 ± 1.5 | 0.66 |

Constant-load exercise test:

|                              | HFNC group (n = 16) | Oxygen group (n = 16) | p value |
|------------------------------|---------------------|-----------------------|---------|
| Δ Time under the prescribed oxygen in daily LTOT (sec) | 430 ± 557 | 262 ± 581 | 0.43 |
| Δ Time under the 6 L/min nasal cannula (sec) | 732 ± 819 | 1036 ± 1163 | 0.43 |
| Δ Time under the HFNC (sec) | 828 ± 700 | 700 ± 840 | 0.66 |

mean ± standard deviation or number (%)

Δ, pre-to-post exercise training change

Abbreviations: 6MWT, 6-minute walking test; LTOT, long-term oxygen therapy.
Table 4
Effects of 4 weeks of exercise training on several parameters, 6-minute walking test, and constant-load exercise test in each group

|                        | HFNC group (n = 16)          | Oxygen group (n = 16)        |
|------------------------|-----------------------------|-----------------------------|
|                        | BL                          | 4 weeks                     | P value | BL                  | 4 weeks                  | P value |
| 6-minute walk distance (m) | 224.1 ± 109.4               | 279.3 ± 103.8               | 0.006   | 210.1 ± 93.0        | 209.6 ± 89.4              | 0.98    |
| Modified Borg Scale for dyspnea on 6MWT | 3.6 ± 2.5                    | 3.6 ± 2.4                   | 0.94    | 3.6 ± 2.1           | 3.9 ± 1.8                 | 0.51    |
| Constant-load exercise test: |                             |                             |         |                     |                          |         |
| Time under the prescribed oxygen in daily LTOT (sec) | 876 ± 858                    | 1340 ± 1178                 | 0.01    | 950 ± 837           | 1211 ± 963                | 0.10    |
| Time under the 6 L/min nasal cannula (sec) | 1065 ± 986                   | 1835 ± 1171                 | 0.005   | 1083 ± 944          | 2119 ± 1102               | 0.004   |
| Time under the HFNC (sec) | 1473 ± 887                   | 2344 ± 1080                 | 0.0007  | 1586 ± 1058         | 2285 ± 1061               | 0.006   |
| %VC (%) | 72.2 ± 15.5                   | 71.0 ± 17.0                 | 0.64    | 74.8 ± 18.8         | 76.5 ± 18.2               | 0.12    |
| FEV1/FVC (%) | 66.7 ± 27.2                  | 65.2 ± 27.1                 | 0.42    | 61.6 ± 23.2         | 62.0 ± 23.0               | 0.61    |
| %DL_{CO} (%) | 55.4 ± 18.5                  | 57.3 ± 21.4                 | 0.19    | 60.8 ± 23.7         | 60.8 ± 23.8               | 0.20    |
| ABGs |                             |                             |         |                     |                          |         |
| pH | 7.401 ± 0.030                | 7.385 ± 0.021               | 0.43    | 7.410 ± 0.036       | 7.398 ± 0.039             | 0.10    |
| PaO₂ (Torr) | 89.6 ± 22.0                  | 87.1 ± 22.4                 | 0.72    | 82.7 ± 23.5         | 85.3 ± 26.0               | 0.49    |
| PaCO₂ (Torr) | 43.7 ± 5.2                   | 44.4 ± 6.2                  | 0.37    | 41.7 ± 7.1          | 42.3 ± 7.0                | 0.53    |
| Blood (fasting) |                             |                             |         |                     |                          |         |
| Adrenaline (pg/mL) | 20.4 ± 14.7                   | 11.6 ± 8.8                  | 0.02    | 20.9 ± 16.1         | 18.6 ± 11.0               | 0.42    |
| Noradrenaline (pg/mL) | 388.0 ± 228.4                | 160.9 ± 95.2               | 0.005   | 370.7 ± 255.7       | 251.8 ± 141.6             | 0.11    |
| CRP (mg/dL) | 0.59 ± 0.58                   | 0.41 ± 0.44                 | 0.04    | 0.40 ± 0.47         | 0.56 ± 0.71               | 0.11    |
### Table 1: Comparison of Pulmonary Function Tests and Arterial Blood Gases Between the HFNC and Oxygen Groups

|                     | HFNC group (n = 16) | Oxygen group (n = 16) |
|---------------------|---------------------|-----------------------|
|                     | BL 4 weeks P value  | BL 4 weeks p value    |
| mean ± standard deviation or number (%) |

Abbreviations: 6MWT, 6-minute walking test; LTOT, long-term oxygen therapy; VC, vital capacity; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; DL_{CO}, diffusion capacity of the lung for carbon monoxide; ABGs, arterial blood gases; PaO\(_2\), partial pressure of arterial oxygen; PaCO\(_2\), partial pressure of arterial carbon dioxide; CRP, C reactive protein

### Secondary outcomes: Change in the duration of the constant-load exercise test after 4 weeks of exercise training

After 4 weeks of exercise training, the durations of the constant-load exercise test under HFNC and 6 L/min nasal cannula in both the HFNC group and oxygen group increased significantly compared with that observed at baseline (Table 4). In contrast, the duration of the constant-load exercise test under prescribed oxygen in daily LTOT in the HFNC group increased significantly compared with that observed at baseline (p = 0.01). However, this increase was not observed in the oxygen group (p = 0.10) (Table 4).

### Effects of 4 weeks of exercise training on variables

Regarding changes in the pulmonary function tests, ABGs, the plasma levels of adrenaline, noradrenaline, and serum CRP prior to and following 4 weeks of exercise training, the plasma levels of adrenaline, noradrenaline, and serum CRP were significantly decreased in the HFNC group compared with the respective baseline values. However, these effects were not observed in the oxygen group (Table 4). ABGs and pulmonary function did not worsen after 4 weeks of exercise training using not only 6L/min oxygen but also HFNC (both extremely high F\(_1\)O\(_2\) and extremely high flow).

### Discussion

The present study was the first randomized, prospective study demonstrating that the use of both high F\(_1\)O\(_2\) and high flow through an HFNC significantly prolonged the duration of the constant-load exercise in CRF patients receiving LTOT versus prescribed oxygen in daily LTOT or a 6 L/min nasal cannula. Moreover, this study found that 4 weeks of training using both high F\(_1\)O\(_2\) and high flow through an HFNC significantly improved the 6MWD compared with using a 6 L/min nasal cannula. Moreover, only patients using an HFNC exhibited a significant decrease in the plasma levels of adrenaline, noradrenaline, and
serum CRP. These results suggest that exercise training using both high F\textsubscript{I}O\textsubscript{2} and high flow through an HFNC may be a preferable modality versus a nasal cannula in CRF patients receiving LTOT.

The American Thoracic Society/European Respiratory Society statement on field walking tests determined an increase of ≥ 30 meters in the 6MWD (with a variability of 25 to 33 meters) as clinically relevant [27]. In the present study, 4 weeks of exercise training using an HFNC improved the 6MWD by 55 meters. Although the sample size in this study was small, the results can be considered significant and definitive.

Several factors for improving the duration of exercise using an HFNC have been considered. Firstly, the F\textsubscript{I}O\textsubscript{2} values induced via an HFNC are more stable and much higher than those of standard oxygen delivery systems [28]. Use of an HFNC can achieve a F\textsubscript{I}O\textsubscript{2} of 1.0, whereas the F\textsubscript{I}O\textsubscript{2} associated with a 6 L/min nasal cannula was estimated to be approximately 0.4. Additionally, an HFNC generates a high flow rate that can exceed the subject’s peak inspiratory flow rate, thus reducing entrainment of room air and dilution of the administered oxygen [29, 30]. Secondly, continuous flushing of the upper airway via an HFNC reduces dead space [31]. This effect may enhance alveolar ventilation if tidal volume is the same, and should increase the oxygen concentration of upper airway at the end of expiration. Thirdly, the high flow rates of an HFNC generate a positive nasopharyngeal pressure which linearly correlates with the administered flow rate in healthy volunteers and patients with stable COPD, IPF, and postcardiac surgery [29, 32–36]. When the mouth of the patients is open, the HFNC produces low positive nasopharyngeal pressure [35] and this condition is frequent during exercise. This low-level positive nasopharyngeal pressure generated using an HFNC may reduce the effort of breathing through enhancing oxygenation by positive end-expiratory pressure (PEEP), providing a low-level inspiratory assistance, and reducing a preload as a counter-PEEP effect. We assume that the use of an HFNC enabled patients to perform prolonged exercise training through the aforementioned mechanisms, resulting in a significant improvement in the 6MWD.

In the present study, our patients had advanced CRF. Thus, their exercise capacity was presumed to be low. To exert the maximal effect of exercise training on exercise capacity, we assessed the maximal effects of an HFNC on long-term exercise training using both maximum F\textsubscript{I}O\textsubscript{2} and near-maximum inspiratory flow rate. The present study showed that 4 weeks of training using an HFNC significantly increased the 6MWD. However, it is unclear whether high flow rate or 100% FiO\textsubscript{2} are responsible for the beneficial effects on exercise capacity. Future studies comparing the effect of long-term exercise training using supplemental oxygen or HFNC with the equivalent F\textsubscript{I}O\textsubscript{2} on the exercise capacity are warranted.

In this study, the HFNC group was used a F\textsubscript{I}O\textsubscript{2} of 1.0 during exercise training. Prolonged hyperoxia has been implicated in organ toxicity processes, such as acute lung injury [37–39]. Systemically, hyperoxia induces peripheral vasoconstriction [40] and, increases production of reactive oxygen species [41]. Recently, arterial hyperoxia is associated with poor hospital outcome in various subsets of critically ill patients [42–44]. On the other hand, there are few studies on the effects of high concentration oxygen administration during exercise training. It has been demonstrated that 100% oxygen administration
during 8 weeks of aerobic high-intensity interval training increased peak oxygen uptake and peak workload to a considerable extent in severe COPD patients [45]. In our study, the HFNC group showed no deterioration in PaO₂ values, pulmonary function tests including diffusion capacity of the lung for carbon monoxide, and the modified Borg Scale for dyspnea on 6MWT (Table 4). These results indicate that 4 weeks of exercise training using an HFNC at F₁O₂ of 1.0 might not induce hyperoxic lung injury. Indeed, the possibility of a much longer period of training using an HFNC with high F₁O₂ inducing hyperoxic lung injury is undeniable.

In addition, the use of a high F₁O₂ during exercise for CRF patients may cause CO₂ retention. In the present study, the partial pressure of arterial carbon dioxide values in the HFNC group were not significantly changed prior to and after 4 weeks of exercise training (Table 3). In addition, there were no significant differences between the three conditions (i.e., prescribed oxygen in daily LTOT vs. 6 L/min via a nasal cannula vs. HFNC at F₁O₂ of 1.0 and 50 L/min) in PtcCO₂ 6 min after initiation of the constant-load exercise test (Fig. 3-C). Based on these results, we assume that the risk of CO₂ retention caused by exercise training using an HFNC at FI₂ of 1.0 is low.

In this study, the plasma levels of adrenaline, noradrenaline, and serum CRP were examined to investigate the effects of exercise training on systemic inflammation and sympathetic activity. The results showed that the HFNC group had a significant reduction in the plasma levels of adrenaline, noradrenaline, and serum CRP after 4 weeks of exercise training compared with the baseline values. It is likely that exercise training reduces the level of CRP by decreasing the production of cytokines in adipose tissue, skeletal muscles, endothelial and blood mononuclear cells, improving endothelial function and insulin sensitivity, and inducing an antioxidant effect [46]. Previous studies reported that the observed enhancement of antioxidant pathways and suppression of pro-oxidant mechanisms in the rostral ventrolateral medulla of rabbits with chronic heart failure contribute to the normalization of sympathetic nerve activity after exercise training [47]. It has been demonstrated that exercise training decreased the level of CRP in the serum [48, 49] and sympathetic activity [50] in patients with COPD. Prolonged exercise training using an HFNC may lead to a decrease in the plasma levels of adrenaline, noradrenaline, and serum CRP.

This study had several limitations. Firstly, the underlying disease in the patients of this study was heterogeneous, so both high F₁O₂ and high flow through an HFNC may have different effects on their underlying disease. In addition, their respiratory failure was severe (thus receiving LTOT). Therefore, it may be difficult to generalize the results of the present study to other patient populations such as those with COPD alone, mild respiratory failure, etc. Secondly, the sample size of this study was small. However, the differences observed in the improvement of the 6MWD after exercise training between the HFNC and oxygen groups were sufficiently large to be considered significant. Thirdly, the oxygen group did not demonstrate a significant improvement in the 6MWD after 4 weeks of exercise training. Respiratory failure in our patients was severe; thus, we assumed that they may be at a high risk of adverse events, such as severe hypoxia and arrhythmia during exercise training. Therefore, we set strict criteria for the termination of the exercise training (ie. SpO₂ ≤ 85%, pulse rate ≥ 135 beats/min) to prevent the
occurrence of adverse events during the test. Although there were no adverse events observed during exercise training in the present study, it is possible that the oxygen group had a shorter exercise training duration owing to more frequent stoppage of the training in response to desaturation or tachycardia. Therefore, significant improvement in the 6MWD after 4 weeks of exercise training may not be observed in the oxygen group.

Conclusion

We demonstrated that 4 weeks of exercise training using both high F\textsubscript{1}O\textsubscript{2} and high flow through an HFNC significantly improved the 6MWD, and decreased systemic inflammation and sympathetic activity. Future research involving large sample sizes or homogenous populations (e.g., patients with COPD alone) is warranted. However, based on the present findings, exercise training using both high F\textsubscript{1}O\textsubscript{2} and high flow through an HFNC is safe and may become an effective modality in CRF patients receiving LTOT.

Abbreviations

ABGs: arterial blood gases; COPD: chronic obstructive pulmonary disease; CRF: chronic respiratory failure; CRP: C-reactive protein; F\textsubscript{1}O\textsubscript{2}: fraction of inspired oxygen; HFNC: high-flow nasal cannula; IPF: interstitial pulmonary fibrosis; LTOT: long-term oxygen therapy; PEEP: positive end-expiratory pressure; PtcCO\textsubscript{2}: transcutaneous carbon dioxide partial pressure; 6MWD: 6-min walking distance; 6MWT: 6-min walking test; SpO\textsubscript{2}: oxygen saturation by pulse oximetry.

 Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the National Hospital Organization Minami-Kyoto Hospital. All patients provided written informed consent prior to their participation.

Consent to publish

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Competing interests

Drs. Yuichi Chihara, Tomomasa Tsuboi, Kensuke Sumi, and Atsuo Sato have no conflicts of interest to disclose.

Funding
This study was supported by Fukuda Foundation for Medical Technology. This financial support was used to purchase SpO$_2$ monitors and TOSCA sensors.

Author Contributions

Conception and research design: Y. C, T. T

Data collection: Y. C, T. T, K. S, A. S

Data analysis and interpretation, and drafting the article: Y. C, T. T.

Critical revision of the article: Y. C, T. T, K. S, A. S

Final approval of the article: Y. C, T. T, K. S, A. S

Acknowledgments

The authors thank Drs. Masayoshi Minakuchi, Susumu Oguri, Hiromasa Tachibana, Shigeki Sakai, and Satoko Tabata for valuable comments and suggestions with regard to this manuscript.

References

1. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13-64.

2. Dowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. 2017;72:610-619.

3. Ong HK, Lee AL, Hill CJ, Holland AE, Denehy L. Effects of pulmonary rehabilitation in bronchiectasis: A retrospective study. Chron Respir Dis. 2011;8:21-30.

4. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. 2006;114:1482-9.

5. Casaburi R, Porszasz J, Burns MR, Carithers ER, Chang RS, Cooper CB. Physiologic benefits of exercise training in chronic rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155:1541-51.

6. Maltais F, LeBlanc P, Jobin J, Bérubé C, Bruneau J, Carrier L, et al. Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155:555-61.

7. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006:CD003793.
8. Neunhäuserer D, Steidle-Kloc E, Weiss G, Kaiser B, Niederseer D, Hartl S, et al. Supplemental Oxygen During High-Intensity Exercise Training in Nonhypoxemic Chronic Obstructive Pulmonary Disease. Am J Med. 2016;129:1185-1193.

9. Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med. 2003;168:1034-42.

10. Rooyackers JM, Dekhuijzen PN, Van Herwaarden CL, Folgering HT. Training with supplemental oxygen in patients with COPD and hypoxaemia at peak exercise. Eur Respir J. 1997;10:1278-84.

11. Garrod R, Paul EA, Wedzicha JA. Supplemental oxygen during pulmonary rehabilitation in patients with COPD with exercise hypoxaemia. 2000;55:539-43.

12. Wadell K, Henriksson-Larsén K, Lundgren R. Physical training with and without oxygen in patients with chronic obstructive pulmonary disease and exercise-induced hypoxaemia. J Rehabil Med. 2001;33:200-5.

13. Scorsone D, Bartolini S, Saporiti R, Braido F, Baroffio M, Pellegrino R, et al. Does a low-density gas mixture or oxygen supplementation improve exercise training in COPD? 2010;138:1133-9.

14. Levy SD, Alladina JW, Hibbert KA, Harris RS, Bajwa EK, Hess DR. High-flow oxygen therapy and other inhaled therapies in intensive care units. 2016;387:1867-78.

15. Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated Humidified High-Flow Nasal Oxygen in Adults: Mechanisms of Action and Clinical Implications. 2015;148:253-261.

16. Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Respir Med. 2009;103:1400-5.

17. Sztrymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med. 2011;37:1780-6.

18. Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, Ricard JD. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. J Crit Care. 2012;27:324.e9-13.

19. Lenglet H, Sztrymf B, Leroy C, Brun P, Dreyfuss D, Ricard JD. Humidified high flow nasal oxygen during respiratory failure in the emergency department: feasibility and efficacy. Respir Care. 2012;57:1873-8.

20. Vitacca M, Paneroni M, Zampogna E, Visca D, Carlucci A, Cirio S, et al. High-Flow Oxygen Therapy During Exercise Training in Patients With Chronic Obstructive Pulmonary Disease and Chronic Hypoxemia: A Multicenter Randomized Controlled Trial. Phys Ther. 2020 Apr 24:pzaa076.

21. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-7.

22. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-81.
23. Gancel PE, Roupie E, Guittet L, Laplume S, Terzi N. Accuracy of a transcutaneous carbon dioxide pressure monitoring device in emergency room patients with acute respiratory failure. Intensive Care Med. 2011;37:348-51.

24. Eberhard P. The design, use, and results of transcutaneous carbon dioxide analysis: current and future directions. Anesth Analg. 2007;105:S48-52.

25. Japan Respiratory Failure Research Group. (1996) Respiratory failure- guideline for diagnosis and treatment-. Medical Review. Tokyo: 16-23. Japanese.

26. Jarosch I, Gloeckl R, Damm E, Schwedhelm AL, Buhrow D, Jerrentrup A, et al. Short-term Effects of Supplemental Oxygen on 6-Min Walk Test Outcomes in Patients With COPD: A Randomized, Placebo-Controlled, Single-blind, Crossover Trial. 2017;151:795-803.

27. Singh SJ, Puhan MA, Andrianopoulos V, Hernandez NA, Mitchell KE, Hill CJ, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1447-78.

28. Chanques G, Riboulet F, Molinari N, Carr J, Jung B, Prades A, et al. Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study. Minerva Anestesiologica. 2013;79:1344-55.

29. Sim MA, Dean P, Kinsella J, Black R, Carter R, Hughes M. Performance of oxygen delivery devices when the breathing pattern of respiratory failure is simulated. 2008;63:938-40.

30. Ritchie JE, Williams AB, Gerard C, Hockey H. Evaluation of a humidified nasal high-flow oxygen system, using oxygraphy, capnography and measurement of upper airway pressures. Anaesthesia Intensive Care. 2011;39:1103-10.

31. Möller W, Celik G, Feng S, Bartenstein P, Meyer G, Oliver E, et al. Nasal high flow clears anatomical dead space in upper airway models. J Appl Physiol (1985). 2015;118:1525-32.

32. Groves N, Tobin A. High flow nasal oxygen generates positive airway pressure in adult volunteers. Aust Crit Care. 2007;20:126-31.

33. Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. 2013;85:319-25.

34. Parke R, McGuinness S, Eccleston M. Nasal high-flow therapy delivers low level positive airway pressure. Br J Anaesth. 2009;103:886-90.

35. Parke RL, Eccleston ML, McGuinness SP. The effects of flow on airway pressure during nasal high-flow oxygen therapy. Respir Care. 2011;56:1151-5.

36. Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF. Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth. 2011;107:998-1004.

37. Kallet RH, Matthay MA. Hyperoxic acute lung injury. Respir Care. 2013;58:123-41.

38. Dias-Freitas F, Metelo-Coimbra C, Roncon-Albuquerque R Jr. Molecular mechanisms underlying hyperoxia acute lung injury. Respir Med. 2016;119:23-28.
39. Kallet RH, Branson RD. Should Oxygen Therapy Be Tightly Regulated to Minimize Hyperoxia in Critically Ill Patients? Respir Care. 2016;61:801-17.

40. Reinhart K, Bloos F, König F, Bredle D, Hannemann L. Reversible decrease of oxygen consumption by hyperoxia. 1991 ;99:690-4.

41. Brueckl C, Kaestle S, Kerem A, Habazettl H, Krombach F, Kuppe H, et al. Hyperoxia-induced reactive oxygen species formation in pulmonary capillary endothelial cells in situ. Am J Respir Cell Mol Biol. 2006;34:453-63.

42. Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K, et al; Emergency Medicine Shock Research Network (EMShockNet) Investigators. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. 2010;303:2165-71.

43. Helmerhorst HJ, Roos-Blom MJ, van Westerloo DJ, de Jonge E. Association Between Arterial Hyperoxia and Outcome in Subsets of Critical Illness: A Systematic Review, Meta-Analysis, and Meta-Regression of Cohort Studies. Crit Care Med. 2015;43:1508-19.

44. Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et al. Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. 2016 ;316:1583-1589.

45. Helgerud J, Bjørgen S, Karlsen T, Husby VS, Steinshamn S, Richardson RS, et al. Hyperoxic interval training in chronic obstructive pulmonary disease patients with oxygen desaturation at peak exercise. Scand J Med Sci Sports. 2010 ;20:e170-6.

46. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45:1563-9.

47. Gao L, Wang W, Liu D, Zucker IH. Exercise training normalizes sympathetic outflow by central antioxidant mechanisms in rabbits with pacing-induced chronic heart failure. 2007;115:3095-102.

48. Sugawara K, Takahashi H, Kasai C, Kiyokawa N, Watanabe T, Fujii S, et al. Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD. Respir Med. 2010;104:1883-9.

49. Wang CH, Chou PC, Joa WC, Chen LF, Sheng TF, Ho SC, et al. Mobile-phone-based home exercise training program decreases systemic inflammation in COPD: a pilot study. BMC Pulm Med. 2014;14:142.

50. Borghi-Silva A, Arena R, Castello V, Simões RP, Martins LE, Catai AM, et al. Aerobic exercise training improves autonomic nervous control in patients with COPD. Respir Med. 2009;103:1503-10.

Figures
Figure 1

Flow chart of trial design. Abbreviations: HFNC, high-flow nasal cannula; FIO2, a fraction of inspired oxygen

Figure 2.

A

\[ p=0.0003 \]

B

\[ p=0.07 \]
Figure 2

Time (A) and modified Borg scale (B) during the constant-load exercise test prior to 4 weeks of exercise training. The time of the constant-load exercise test using an HFNC was significantly longer than that reported with prescribed oxygen or a 6 L/min nasal cannula (A). The modified Borg scale for dyspnea at the termination of the constant-load exercise test under the HFNC tended to be lower compared with that observed under the 6 L/min nasal cannula (B). Data are presented as mean values ± standard deviation. Abbreviations: LTOT, long-term oxygen therapy; HFNC, high-flow nasal cannula.

Abbreviations: LTOT, long-term oxygen therapy; HFNC, high-flow nasal cannula

Figure 3

Changes in SpO2 (A), pulse rate (B), and PtcCO2 (C) at 0 and 6 min of the constant-load exercise test prior to 4 weeks of exercise training. A single asterisk indicates p < 0.05 between the two conditions. Abbreviations: LTOT, long-term oxygen therapy; HFNC, high-flow nasal cannula; SpO2, percutaneous oxygen saturation; PtcCO2, transcutaneous carbon dioxide partial.
Figure 4

Change in the 6-minute walking distance in the HFNC and oxygen groups after 4 weeks of exercise training. Abbreviations: HFNC, high-flow nasal cannula

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- StudyProtocol.docx
- CONSORT2010Checklist.doc